Abstract

Accumulating evidence has implicated impaired extracellular matrix (ECM) clearance as a key factor in fibrotic disease. Despite decades of research elucidating the effectors of ECM clearance, relatively little is understood regarding the upstream regulation of this process. Collagen is the most abundant constituent of normal and fibrotic ECM in mammalian tissues. Its catabolism occurs through extracellular proteolysis and cell-mediated uptake of collagen fragments for intracellular degradation. Given the paucity of information regarding the regulation of this latter process, here we execute unbiased genome-wide screens to understand the molecular underpinnings of cell-mediated collagen clearance. Using this approach, we discover a mechanism through which collagen biosynthesis is sensed by cells internally and directly regulates clearance of extracellular collagen. The sensing mechanism appears to be dependent on endoplasmic reticulum-resident protein SEL1L and occurs via a noncanonical function of this protein. This pathway functions as a homeostatic negative feedback loop that limits collagen accumulation in tissues. In human fibrotic lung disease, the induction of this collagen clearance pathway by collagen synthesis is impaired, thereby contributing to the pathological accumulation of collagen in lung tissue. Thus, we describe cell-autonomous, rheostatic collagen clearance as an important pathway of tissue homeostasis.

Mechanisms regulating collagen clearance may be useful for treating fibrosis. Here, the authors conducted functional genome-wide screens and found that collagen biosynthesis directly regulates collagen clearance via a noncanonical function of SEL1L.

Details

Title
Genome-wide screens identify SEL1L as an intracellular rheostat controlling collagen turnover
Author
Podolsky, Michael J. 1   VIAFID ORCID Logo  ; Kheyfets, Benjamin 1 ; Pandey, Monika 1 ; Beigh, Afaq H. 1 ; Yang, Christopher D. 2   VIAFID ORCID Logo  ; Lizama, Carlos O. 2   VIAFID ORCID Logo  ; Datta, Ritwik 2 ; Lin, Liangguang L. 3   VIAFID ORCID Logo  ; Wang, Zhihong 3   VIAFID ORCID Logo  ; Wolters, Paul J. 4   VIAFID ORCID Logo  ; McManus, Michael T. 5   VIAFID ORCID Logo  ; Qi, Ling 3   VIAFID ORCID Logo  ; Atabai, Kamran 6   VIAFID ORCID Logo 

 Weill Cornell Medical College, Department of Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X) 
 University of California, Cardiovascular Research Institute, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 University of Virginia School of Medicine, Department of Molecular Physiology and Biological Physics, Charlottesville, USA (GRID:grid.27755.32) (ISNI:0000 0000 9136 933X) 
 University of California, Department of Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 University of California, Department of Microbiology and Immunology and UCSF Diabetes Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 University of California, Cardiovascular Research Institute, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Department of Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Lung Biology Center, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
Pages
1531
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2928720227
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.